Whole blood has made a remarkable comeback in trauma resuscitation. Physiologically, the rationale is compelling, and observational studies have suggested improved survival. But the recent randomized TOWAR and SWiFT trials have challenged the assumption that whole blood is clearly superior to component therapy.
In this episode of Trauma ICU Rounds, we review the rationale for low-titer group O whole blood (LTOWB), the major observational data supporting its use, what TOWAR and SWiFT actually showed, and how these findings should influence contemporary damage-control resuscitation.
Topics include:
Low-titer group O whole blood (LTOWB)
Observational versus randomized evidence
TOWAR and SWiFT
Whole blood versus balanced component therapy
Integrating whole blood into massive hemorrhage protocols
Calcium, warming, TXA and hemorrhage control
RhD considerations in females of childbearing potential
The central question: whole blood clearly works as a resuscitation product—but is it actually better than excellent component therapy?
Full notes, graphics and references: traumaicurounds.ca
Follow @traumaicurounds on Instagram and TikTok, and subscribe on YouTube for new trauma and critical care teaching.
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr. Dennis Kim. Innehållet i podden är skapat av Dr. Dennis Kim och inte av,
eller tillsammans med, Poddtoppen.